Morgan Stanley Sacks Allergan … Co-Signs ‘Shock Exchange’
Allergan has shocked the financial markets earlier this month when it sold its Restagis patents to St. Regis Mohawk tribe. The tribe has sovereign...
Allergan Stymies Another Restasis Competitor. Where’s Sherrod Brown?
Allergan (AGN) has dominated the financial news cycle since it agreed to sell its Restasis patents to St. Regis Mohawks in order to protect...
Alexion’s Growth Is Dead
Last week Alexion Pharmaceuticals (ALXN) announced it was moving its headquarters from New Haven, CT to Boston/Cambridge:
The new crew in charge of Alexion $ALXN...
Endo Is Not Out Of The Woods Yet
There is a war being fought over rising drug prices and Endo Pharmaceuticals (ENDP) is right in the middle of it. It has gotten...
Is Teva’s $1 Billion Paragard Sale Much Ado About Nothing?
Teva (TEVA) has had some exciting news to present over the past week. It hired 30-year industry veteran Kare Schultz as its full-time CEO....
Allergan: Is Imprimis Spat Another Ruse To Crush Restasis Competitor?
Earlier this month Allergan (AGN) had Wall Street abuzz after it sold its Restasis patents to St. Regis Mohawk Tribe to protect them from...
Mylan Attacks Allergan’s ‘Desperate’ Measures To Protect Restasis
The Restasis patent battle between Mylan (MYL) and Allergan is heating up. Mylan heavily criticized Allergan for partnering with St. Regis Mohawks to protect...
Shocking The Street: Ratings Downgrade Could Wreck Allergan
The stock market keeps going up and up, regardless of how poor the economy is. Buoyed by former President Barack Obama, Janet Yellen, Ben...
Aldeyra Spikes On Clinical Improvement In Dry Eye Med
Aldeyra Therapeutics (ALDX) claims its dry eye treatment, ADX-102, demonstrated "statistically and clinically significant improvements" in a midstage trial:
The phase 2a test, which was...
Has Valeant Run Out Of Catalysts?
Valeant (VRX) bulls continue to promote the stock and deny reality. Management has talked up asset sales and product development, but they have yet...
